Año: 2024
Journal Impact Factor (JIF): 8.50
| Categoría | Edición | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|---|
| INFECTIOUS DISEASES | SCIE | 5/137 | Q1 | T1 | D1 |
| MICROBIOLOGY | SCIE | 14/163 | Q1 | T1 | D1 |
Año: 2024
Journal Citation Indicator (JCI): 2,350
| Categoría | Posición | Cuartil | Tercil | Decil | Percentil |
|---|---|---|---|---|---|
| INFECTIOUS DISEASES | 5/137 | Q1 | T1 | D1 | 96,72 |
| MICROBIOLOGY | 9/163 | Q1 | T1 | D1 | 94,79 |
Año:
2024
CiteScore:
22,400
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Infectious Diseases | 10/357 | Q1 | T1 | D1 |
| Microbiology (medical) | 6/148 | Q1 | T1 | D1 |
SJR año:
2024
Factor de Impacto:
2,742
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Infectious Diseases | 14/361 | Q1 | T1 | D1 |
| Medicine (miscellaneous) | 97/2523 | Q1 | T1 | D1 |
| Microbiology (medical) | 8/150 | Q1 | T1 | D1 |
| Agencia | Código de Proyecto |
|---|---|
| EFPIA | - |
| European Union | - |
| Innovative Medicines Initiative 2 Joint Undertaking | 101034420 |
| # | Autor | Afiliación |
|---|---|---|
| 1 | Kingston, Rhys | UK Health Security Agency (United Kingdom) |
| 2 | Vella, Venanzio | GlaxoSmithKline SpA (Italy) |
| 3 | Pouwels, Koen B. | University of Oxford Medical Sciences Division (United Kingdom) |
| 4 | Schmidt, Johannes E. | GlaxoSmithKline SpA (Italy) |
| 5 | Abdelatif El-Abasiri, Radwa A. | University of Oxford Medical Sciences Division (United Kingdom) |
| 6 | Reyna-Villasmil, Eduardo | Hospital Universitario Virgen Macarena (Spain) |
| 7 | Hassoun-Kheir, Nasreen | Hôpitaux universitaires de Genève (Switzerland) |
| 8 | Harbarth, Stephan | Hôpitaux universitaires de Genève (Switzerland) |
| 9 | Rodríguez-Baño, Jesús | Hospital Universitario Virgen Macarena (Spain) |
| 10 | Tacconelli, Evelina | Università degli Studi di Verona (Italy) |
| 11 | Arieti, Fabiana | Università degli Studi di Verona (Italy) |
| 12 | Gladstone, Beryl Primrose | Universitätsklinikum Tübingen Medizinische Fakultät (Germany) |
| 13 | de Kraker, Marlieke E.A. | Hôpitaux universitaires de Genève (Switzerland) |
| 14 | Naylor, Nichola R. | UK Health Security Agency (United Kingdom) |
| 15 | Robotham, Julie V. | UK Health Security Agency (United Kingdom) |
| 16 | Lorenzo Argante, | GlaxoSmithKline SpA (Italy) |
| 17 | Barana, Benedetta | Università degli Studi di Verona (Italy) |
| 18 | Cappelli, Eva | Università degli Studi di Verona (Italy) |
| 19 | De Rui, Maria Elena | Università degli Studi di Verona (Italy) |
| 20 | Galia, Liliana | Università degli Studi di Verona (Italy) |
| 21 | Geurtsen, Jeroen | Janssen Vaccines & Prevention B.V. (Netherlands) |
| 22 | Guedes, Mariana | Hospital Universitario Virgen Macarena; Centro Hospitalar Universitário de São João (Spain) |
| 23 | Mejia, Jorly | Universidad de Sevilla; Hôpitaux universitaires de Genève (Switzerland) |
| 24 | Palladino, Andrea | GlaxoSmithKline SpA (Italy) |
| 25 | Pezzani, Maria Diletta | Università degli Studi di Verona (Italy) |
| 26 | Piljic, Alen | Università degli Studi di Verona (Italy) |